consortium / KUL
Horizon EIC transition · Project 101292011
KU Leuven
Katholieke Universiteit Leuven (KUL) is one of Europe’s oldest universities, which consistently ranks amongst the world’s best universities and is widely regarded as one of the most innovative research institutions.
Role in GLIOBREAK
KU Leuven Laboratory for Precision Cancer Medicine (LPCM) leads WP6 (Biomarker Development), integrating single-cell omics (LISCO lab) and tumour immunology (LTII lab) to identify and validate predictive biomarkers for BEA-17 response. The work builds directly on the GLIOMATCH project, coordinated by LPCM, which generated a comprehensive single-cell atlas of GBM tumour–host interactions that serves as the scientific foundation for the GLIOBREAK biomarker strategy.
Leuven Institute for single-cell omics (KUL-LISCO)
The KU Leuven Institute for Single Cell Omics (LISCO) nucleates interdisciplinary expertise in single-cell and spatial multi-omics to investigate normal development, aging and disease processes in humans and other organisms, down to the biology of unicellular life forms. LISCO aims to develop innovative single-cell analysis technologies and high-throughput platforms to enable breakthrough biomedical and biological science that transcends an individual research lab, to pioneer and set standards in disruptive single-cell technologies and research, and to translate technologies and biomedical discoveries to the clinic. It unites researchers from over 55 groups from KUL, UZ Leuven and VIB-KU Leuven, creating a framework for academic and industrial collaboration, service provision, and training of the next-generation researchers.
Laboratory for Tumor Immunology and Immunotherapy (KUL-LTII)
At the Laboratory for Tumor Immunology and Immunotherapy, a part of the Leuven cancer institute (LKI), science is driven by one profound belief: the human immune system may hold the key to transforming cancer care. The research stands at the frontier where biology, medicine, and hope meet. By studying how the immune system interacts with tumors, the team seeks not only to understand cancer, but to teach the body itself how to fight back. Both for ovarian cancer and brain cancer, their work combines patient-based immune profiling with advanced preclinical immunotherapy models — turning clinical observations into future treatments.
What distinguishes the laboratory is its translational approach: scientific discoveries are continuously connected to clinical application. Each dataset, tissue sample, and experimental model contributes to a larger objective — developing therapies that are more targeted, personalized, and biologically effective.
The team itself reflects the interdisciplinary nature of contemporary biomedical science. Under the leadership of Professor An Coosemans, a multidisciplinary team of researchers collaborate within a highly integrated research environment.
What distinguishes the laboratory is its translational approach: scientific discoveries are continuously connected to clinical application. Each dataset, tissue sample, and experimental model contributes to a larger objective — developing therapies that are more targeted, personalized, and biologically effective.
The team itself reflects the interdisciplinary nature of contemporary biomedical science. Under the leadership of Professor An Coosemans, a multidisciplinary team of researchers collaborate within a highly integrated research environment.
